The Category 2 Ban and the 2026 Reclassification In 2023, the FDA pulled 19 of the most popular peptides BPC-157, TB-500, CJC-1295, among others off the compounding-permitted list and placed them on the restricted Category 2 list, citing safety concerns, impurity issues, and a lack of clinical data
One potential explanation for this phenomenon is the accumulation of fatty acids in the liver, which may exceed its oxidative capacity
Prevents & treats selenium deficiency
Clear answers and peace of mind are just a heartbeat away
They do not involve GLOW Blend, NovaGlo Research products, or any material sold by NovaGlo
Store per the peptide storage guide